MX370519B - Sulfonamidas con sustitucion biarilo y su uso. - Google Patents

Sulfonamidas con sustitucion biarilo y su uso.

Info

Publication number
MX370519B
MX370519B MX2015006544A MX2015006544A MX370519B MX 370519 B MX370519 B MX 370519B MX 2015006544 A MX2015006544 A MX 2015006544A MX 2015006544 A MX2015006544 A MX 2015006544A MX 370519 B MX370519 B MX 370519B
Authority
MX
Mexico
Prior art keywords
compounds
substituted biaryl
amelioration
prevention
treatment
Prior art date
Application number
MX2015006544A
Other languages
English (en)
Other versions
MX2015006544A (es
Inventor
M Fung Leah
A Swindlehurst Cathy
W H Chan Kyle
w sullivan Robert
Original Assignee
Novomedix Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novomedix Llc filed Critical Novomedix Llc
Publication of MX2015006544A publication Critical patent/MX2015006544A/es
Publication of MX370519B publication Critical patent/MX370519B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/21—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

En la presente se proporcionan los compuestos sulfonamida con sustitución biarilo que tienen la fórmula (I), (ver Fórmula) las composiciones farmacéuticas que contienen los compuestos, los métodos para su preparación y los métodos de uso. Los compuestos que se proporcionan en la presente son útiles para el tratamiento, prevención y/o mejoría de diversos trastornos, que incluyen cáncer y trastornos proliferativos. En una modalidad, los compuestos que se proporcionan en la presente modulan el inicio de la traducción de las proteínas. En una modalidad, los compuestos que se proporcionan en la presente se utilizan en combinación con cirugía, terapia de radiación, inmunoterapia y/o uno o más medicamentos anti-cáncer adicionales para el tratamiento, prevención y/o mejoría de cáncer y trastornos proliferativos.
MX2015006544A 2012-11-30 2013-11-27 Sulfonamidas con sustitucion biarilo y su uso. MX370519B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261732218P 2012-11-30 2012-11-30
PCT/US2013/072303 WO2014085633A1 (en) 2012-11-30 2013-11-27 Substituted biaryl sulfonamides and the use thereof

Publications (2)

Publication Number Publication Date
MX2015006544A MX2015006544A (es) 2015-09-24
MX370519B true MX370519B (es) 2019-12-17

Family

ID=49765712

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015006544A MX370519B (es) 2012-11-30 2013-11-27 Sulfonamidas con sustitucion biarilo y su uso.

Country Status (14)

Country Link
US (6) US9156781B2 (es)
EP (2) EP3447046A1 (es)
JP (1) JP6313779B2 (es)
KR (1) KR102180342B1 (es)
CN (2) CN107698470A (es)
AU (1) AU2013352106B2 (es)
CA (1) CA2892227C (es)
DK (1) DK2925718T3 (es)
ES (1) ES2689921T3 (es)
MX (1) MX370519B (es)
NZ (1) NZ630786A (es)
SG (1) SG11201504041WA (es)
WO (1) WO2014085633A1 (es)
ZA (1) ZA201503797B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107698470A (zh) * 2012-11-30 2018-02-16 诺沃梅迪科斯有限公司 取代的二芳基磺酰胺及其用途
AU2015213721B2 (en) 2014-02-07 2021-05-20 Effector Therapeutics, Inc. Methods for treating fibrotic disease
CA3093749A1 (en) * 2018-03-28 2019-10-03 Blade Therapeutics, Inc. Method of treating fibrotic disease
JP2021008453A (ja) * 2019-07-02 2021-01-28 エフェクター・セラピューティクス，インコーポレーテッド 翻訳阻害剤およびその使用
US20230201144A1 (en) * 2020-05-29 2023-06-29 Novomedix, Llc Biarylsulfonamides and pharmaceutical compositions thereof, and their use for treating fibrotic lung disease

Family Cites Families (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1379918A (fr) 1962-12-17 1964-11-27 Bayer Ag Nouveaux agents acaricides et leur procédé de fabrication
NL301745A (es) * 1962-12-17
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4410545A (en) 1981-02-13 1983-10-18 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4328245A (en) 1981-02-13 1982-05-04 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4409239A (en) 1982-01-21 1983-10-11 Syntex (U.S.A.) Inc. Propylene glycol diester solutions of PGE-type compounds
ES8702440A1 (es) 1984-10-04 1986-12-16 Monsanto Co Un procedimiento para la preparacion de una composicion de polipeptido inyectable sustancialmente no acuosa.
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
US5612059A (en) 1988-08-30 1997-03-18 Pfizer Inc. Use of asymmetric membranes in delivery devices
JPH0272151A (ja) * 1988-09-08 1990-03-12 Nippon Tokushu Noyaku Seizo Kk ３，５‐ジ置換ベンゼンスルホン酸アニリド類及び農業用殺菌剤
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
PH30995A (en) 1989-07-07 1997-12-23 Novartis Inc Sustained release formulations of water soluble peptides.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5585112A (en) 1989-12-22 1996-12-17 Imarx Pharmaceutical Corp. Method of preparing gas and gaseous precursor-filled microspheres
IT1246382B (it) 1990-04-17 1994-11-18 Eurand Int Metodo per la cessione mirata e controllata di farmaci nell'intestino e particolarmente nel colon
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5543390A (en) 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University Covalent microparticle-drug conjugates for biological targeting
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
AU4406793A (en) 1992-06-04 1993-12-30 Clover Consolidated, Limited Water-soluble polymeric carriers for drug delivery
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
TW333456B (en) 1992-12-07 1998-06-11 Takeda Pharm Ind Co Ltd A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide.
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
US6096331A (en) 1993-02-22 2000-08-01 Vivorx Pharmaceuticals, Inc. Methods and compositions useful for administration of chemotherapeutic agents
US6537579B1 (en) 1993-02-22 2003-03-25 American Bioscience, Inc. Compositions and methods for administration of pharmacologically active compounds
US6753006B1 (en) 1993-02-22 2004-06-22 American Bioscience, Inc. Paclitaxel-containing formulations
US5498421A (en) 1993-02-22 1996-03-12 Vivorx Pharmaceuticals, Inc. Composition useful for in vivo delivery of biologics and methods employing same
US5439686A (en) 1993-02-22 1995-08-08 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
US6749868B1 (en) 1993-02-22 2004-06-15 American Bioscience, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US6274552B1 (en) 1993-03-18 2001-08-14 Cytimmune Sciences, Inc. Composition and method for delivery of biologically-active factors
US5985307A (en) 1993-04-14 1999-11-16 Emory University Device and method for non-occlusive localized drug delivery
US5523092A (en) 1993-04-14 1996-06-04 Emory University Device for local drug delivery and methods for using the same
US6087324A (en) 1993-06-24 2000-07-11 Takeda Chemical Industries, Ltd. Sustained-release preparation
US6004534A (en) 1993-07-23 1999-12-21 Massachusetts Institute Of Technology Targeted polymerized liposomes for improved drug delivery
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US5759542A (en) 1994-08-05 1998-06-02 New England Deaconess Hospital Corporation Compositions and methods for the delivery of drugs by platelets for the treatment of cardiovascular and other diseases
US5660854A (en) 1994-11-28 1997-08-26 Haynes; Duncan H Drug releasing surgical implant or dressing material
US6316652B1 (en) 1995-06-06 2001-11-13 Kosta Steliou Drug mitochondrial targeting agents
US5798119A (en) 1995-06-13 1998-08-25 S. C. Johnson & Son, Inc. Osmotic-delivery devices having vapor-permeable coatings
WO1997001331A2 (en) 1995-06-27 1997-01-16 Takeda Chemical Industries, Ltd. Method of producing sustained-release preparation
TW448055B (en) 1995-09-04 2001-08-01 Takeda Chemical Industries Ltd Method of production of sustained-release preparation
JP2909418B2 (ja) 1995-09-18 1999-06-23 株式会社資生堂 薬物の遅延放出型マイクロスフイア
US6039975A (en) 1995-10-17 2000-03-21 Hoffman-La Roche Inc. Colon targeted delivery system
US5980945A (en) 1996-01-16 1999-11-09 Societe De Conseils De Recherches Et D'applications Scientifique S.A. Sustained release drug formulations
US5977163A (en) 1996-03-12 1999-11-02 Pg-Txl Company, L. P. Water soluble paclitaxel prodrugs
TW345603B (en) 1996-05-29 1998-11-21 Gmundner Fertigteile Gmbh A noise control device for tracks
US6264970B1 (en) 1996-06-26 2001-07-24 Takeda Chemical Industries, Ltd. Sustained-release preparation
US6419961B1 (en) 1996-08-29 2002-07-16 Takeda Chemical Industries, Ltd. Sustained release microcapsules of a bioactive substance and a biodegradable polymer
AU722289B2 (en) 1996-10-01 2000-07-27 Aptalis Pharmatech, Inc. Taste-masked microcapsule compositions and methods of manufacture
CA2217134A1 (en) 1996-10-09 1998-04-09 Sumitomo Pharmaceuticals Co., Ltd. Sustained release formulation
EP0839525B1 (en) 1996-10-31 2004-08-04 Takeda Chemical Industries, Ltd. Sustained-release preparation
US6131570A (en) 1998-06-30 2000-10-17 Aradigm Corporation Temperature controlling device for aerosol drug delivery
DE69719367T2 (de) 1996-12-20 2003-10-16 Takeda Chemical Industries, Ltd. Verfahren zur herstellung einer zusammensetzung mit verzoegerter abgabe
US5891474A (en) 1997-01-29 1999-04-06 Poli Industria Chimica, S.P.A. Time-specific controlled release dosage formulations and method of preparing same
US6120751A (en) 1997-03-21 2000-09-19 Imarx Pharmaceutical Corp. Charged lipids and uses for the same
US6060082A (en) 1997-04-18 2000-05-09 Massachusetts Institute Of Technology Polymerized liposomes targeted to M cells and useful for oral or mucosal drug delivery
US6350458B1 (en) 1998-02-10 2002-02-26 Generex Pharmaceuticals Incorporated Mixed micellar drug deliver system and method of preparation
US6613358B2 (en) 1998-03-18 2003-09-02 Theodore W. Randolph Sustained-release composition including amorphous polymer
US6048736A (en) 1998-04-29 2000-04-11 Kosak; Kenneth M. Cyclodextrin polymers for carrying and releasing drugs
KR19990085365A (ko) 1998-05-16 1999-12-06 허영섭 지속적으로 약물 조절방출이 가능한 생분해성 고분자 미립구 및그 제조방법
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6271359B1 (en) 1999-04-14 2001-08-07 Musc Foundation For Research Development Tissue-specific and pathogen-specific toxic agents and ribozymes
AU2001252711A1 (en) 2000-04-15 2001-10-30 Byung-Wook Jo Aqueous-prodrug compound comprising moiety of paclitxel or derivatives thereof, method of preparing same and pharmaceutical composition comprising same
MXPA03001771A (es) 2000-08-30 2003-06-04 Pfizer Prod Inc Formulaciones de liberacion sostenida para secretagogos de hormona del crecimiento.
AU2002317377A1 (en) * 2001-07-20 2003-03-03 Cancer Research Technology Limited Biphenyl apurinic/apyrimidinic site endonuclease inhibitors to treat cancer
GB0215650D0 (en) * 2002-07-05 2002-08-14 Cyclacel Ltd Bisarylsufonamide compounds
US20040068012A1 (en) * 2002-10-08 2004-04-08 Comess Kenneth M. Sulfonamides having antiangiogenic and anticancer activity
US7491718B2 (en) * 2002-10-08 2009-02-17 Abbott Laboratories Sulfonamides having antiangiogenic and anticancer activity
LT1585548T (lt) 2002-12-09 2018-09-25 Abraxis Bioscience, Llc Farmakologinių agentų kompozicijos ir įvedimo būdai
NZ595313A (en) 2005-02-18 2013-03-28 Abraxis Bioscience Llc The Use Of Nanoparticles Comprising Rapamycin Or Taxane In The Treatment Of Proliferative Diseases
JP2007065626A (ja) * 2005-08-01 2007-03-15 Fujifilm Holdings Corp 黒白熱現像感光材料および画像形成方法
GB0526252D0 (en) * 2005-12-22 2006-02-01 Novartis Ag Organic compounds
WO2008114831A1 (ja) * 2007-03-20 2008-09-25 National University Corporation Okayama University スルホンアミド基を有する抗菌剤
SG186229A1 (en) 2010-06-07 2013-01-30 Novomedix Llc Furanyl compounds and the use thereof
CN107698470A (zh) * 2012-11-30 2018-02-16 诺沃梅迪科斯有限公司 取代的二芳基磺酰胺及其用途

Also Published As

Publication number Publication date
CN104955801B (zh) 2017-10-31
ES2689921T3 (es) 2018-11-16
AU2013352106B2 (en) 2018-04-26
US20200062700A1 (en) 2020-02-27
MX2015006544A (es) 2015-09-24
CA2892227A1 (en) 2014-06-05
US20170158627A1 (en) 2017-06-08
ZA201503797B (en) 2017-09-27
KR20150118088A (ko) 2015-10-21
US9156781B2 (en) 2015-10-13
KR102180342B1 (ko) 2020-11-18
US9604924B2 (en) 2017-03-28
US20160016899A1 (en) 2016-01-21
DK2925718T3 (en) 2018-10-22
CN107698470A (zh) 2018-02-16
SG11201504041WA (en) 2015-06-29
US11713293B2 (en) 2023-08-01
CN104955801A (zh) 2015-09-30
NZ630786A (en) 2017-03-31
CA2892227C (en) 2020-12-15
JP6313779B2 (ja) 2018-04-18
US10040757B2 (en) 2018-08-07
US20180327353A1 (en) 2018-11-15
WO2014085633A1 (en) 2014-06-05
JP2016502540A (ja) 2016-01-28
AU2013352106A1 (en) 2015-06-11
EP3447046A1 (en) 2019-02-27
US20220002240A1 (en) 2022-01-06
EP2925718B1 (en) 2018-08-01
US20140155477A1 (en) 2014-06-05
EP2925718A1 (en) 2015-10-07

Similar Documents

Publication Publication Date Title
CY1122966T1 (el) 5-βρωμο-2,6-δι-(1η-πυραζολ-1-υλ)πυριμιδιν-4-αμινη για χρηση στη θεραπευτικη αγωγη καρκινου
AU2018260808A1 (en) Compounds and uses thereof for the modulation of hemoglobin
MX2017015938A (es) Inhibidores de ezh2 para el tratar linfomas.
MX2016007351A (es) Terapia de combinacion para tratar cancer.
WO2015103438A3 (en) Oncolytic virus adjunct therapy with agents that increase virus infectivity
MX2020001555A (es) Preparaciones terapéuticas de glicanos y métodos relacionados con estas.
MX2021000848A (es) Compuestos y sus usos para modular la hemoglobina.
SG10201902664RA (en) Combination therapy for treating cancer
BR112016006994A2 (pt) inibidores de erk e métodos de uso
HK1255141A1 (zh) 包含抗folr1免疫缀合物的治疗组合
BR112014031088A2 (pt) métodos para o tratamento de câncer pancreático usando terapias de combinação que compreendem irinotecano lipossomal
CY1120742T1 (el) Ρυθμιστες του υποδοχεα χ ηπατος (lxr) για τη θεραπεια δερματικων ασθενειων, διαταραχων και καταστασεων
EA201591925A1 (ru) Терапевтические композиции и их применение
MY195081A (en) Pladienolide Pyridine Compounds and Methods of use
MX356755B (es) Compuestos de tipo fumagilol y metodos para su elaboración y uso.
PH12015502616A1 (en) Pharmaceutical combination comprising metformin and dihydroquercetin and its use for the treatment of cancer
BR112017019728A2 (pt) combinações e formulações de dose fixa compreendendo etc1002 e uma ou mais estatinas e método para tratar ou reduzir o risco de doença cardiovascular
MX2015006544A (es) Sulfonamidas con sustitucion biarilo y su uso.
MX367469B (es) Compuestos furanilo y su uso.
CY1119532T1 (el) (s)-πιρλινδολη και τα φαρμακευτικως αποδεκτα αλατα αυτης για χρηση στην ιατρικη
BR112018002530A2 (pt) combinações e usos e tratamentos destas
UY33219A (es) Cetoenoles cíclicos para terapias
NZ734750A (en) Cancer therapy with a parvovirus combined with bevacizumab
TW201713323A (en) Therapeutic compositions and methods of use thereof
CY1119522T1 (el) (r)- πιρλινδολη και τα φαρμακευτικως αποδεκτα αλατα αυτης για χρηση στην ιατρικη

Legal Events

Date Code Title Description
FG Grant or registration